Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient. –

Leeyaphan, C. Betts, R. The working diagnosis was recurrent herpes simplex keratitis. Biologic response modifiers. Infections with herpes simplex virus (HSV) are among the most common chronic viral infections in Europe. These references are in PubMed. We are indebted to Mr.

Because foscarnet does not require activation by viral thymidine kinase, it retains activity against HSV strains with absent, partially reduced, or altered production of thymidine kinase. Herpesviruses are among the most prevalent human pathogens, and most individuals are infected with multiple species by the time they reach adulthood. It occurs in two distinct adult populations: immunocompromised adults and pregnant women in the late second or third trimester [2, 3]. HSV-1 and HSV-2 infect mucosal surfaces and abraded skin and transit within sensory nerve fibers to the ganglia, where they establish lifelong latency. Complete: Journals that are no longer published or that have been combined with another title. The 50% inhibitory dose of acyclovir-susceptible, thymidine kinase-positive isolates ranged from 0.01 to 1.1 micrograms/ml. Dunne EF, Whitehead S, Sternberg M, Thepamnuay S, Leelawiwat W, McNicholl JM, et al.

Absorbed: Journals that are combined with another title. Absorbed: Journals that are combined with another title. Such a significant change in management strategy at this time is premature. Absorbed: Journals that are combined with another title. Reactivation can result in the production of infectious virus that travels back down peripheral nerves, where it can produce clinically overt lesions or be shed asymptomatically [1]. Another recent trial found that 400 mg of acyclovir twice daily reduced plasma HIV-1 levels by .25 log10 copies/mL and the risk of HIV-1 disease progression by 16% but failed to reduce HIV-1 transmission to sexual partners [1, 8]. Note: In calculating the moving wall, the current year is not counted.


In rare instances, a publisher has elected to have a “zero” moving wall, so their current issues are available in JSTOR shortly after publication. In this earlier trial, 73% of the placebo group developed culture-positive HSV infection from a mucocutaneous lesion, while none in the prophylaxed group became positive. By contrast, a total of 5 unique nucleotide and 4 distinct amino acid changes were detected in 7 of 8 HSV-2 patients. Note: In calculating the moving wall, the current year is not counted. Note: In calculating the moving wall, the current year is not counted. For this group, the mean duration of pain was reduced by 36% (P = .02)and the mean healing time to loss of crust by 27% (P = .03). Acyclovir-resistant HSV was recovered from one acyclovir recipient while receiving prophylactic acyclovir, and from two placebo recipients during subsequent administration of therapeutic acyclovir.

The characteristics of the patients are summarized in the table. There were no significant differences between the remaining 17 acyclovir and 21 control patients in age, sex, distribution of primary diagnostic categories, and severity of primary illness. Five patients (45%) had isolates that harbored point mutations leading to amino acid substitutions that could be associated with Acy resistance. After 1-2 years, I never experienced testicular pain again. The total number of positive ocular samples was 14 during the first week of dual treatment (5/5 animals positive) and decreased to 2 positive samples (2/5 animals) during the fourth week of dual treatment. INTERVENTION: Participants were randomly assigned to receive either acyclovir, 400 mg twice daily for 70 days, followed by a 14-day washout period, and then placebo for 70 days, or the study medications in the reverse order. Moving walls are generally represented in years.

Treatment was given either for 32 days or until the patients were discharged from the hospital or until a culture-positive herpes simplex virus infection was found. All nine culture-positive placebo recipients developed associated lesions during prophylaxis compared to four of six acyclovir recipients. As expected, a course of acyclovir did not prevent later recurrences of the herpes virus infections. The uptake, distribution, and anabolism of the nucleoside analog 9-(2-hydroxyethoxymethyl) guanine (acyclovir) were compared in herpes simplex virus-infected and uninfected mice. HSV DNA quantitation has the potential for estimating the effects of antiviral therapy. A total of 107 patients from centers in Burlington, Vermont, and San Diego, California, were entered into the study within 48 hours of the onset of lesions. In 23 of these episodes, the treatments were extended for 1 to 6 months using two to five capsules a day with the aim of suppressing expected recurrences.

He had been pretreated extensively with acyclovir. The biochemical properties of four acyclovir-resistant mutants are described. Acyclovir or placebo was administered for 18 days, starting three days before transplantation. Rapid resolution of lesions occurred, and the fetus was delivered at term without evident abnormalities. This article has been cited by other articles in PMC. This article has been cited by other articles in PMC. PubMed Health.

This article has been cited by other articles in PMC.